TY  - JOUR

T1  - Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.

JO  - Health Technol Assess

PY  - 2009/06/01

AU  - Ward S

AU  - Pilgrim H

AU  - Hind D

ED  - 

DO  - DOI: 10.3310/hta13suppl1/01

VL  - 13 Suppl 1

SP  - 1

EP  - 6

Y2  - 2024/10/22

ER  -